News – Page 1172 – Endpoints News

Biotech venture champion Bill Maris is exiting GV. What’s next?

9 years ago

Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke?

9 years ago

Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead

9 years ago

Protagonist’s IPO option delivers a $90M payoff for early-stage peptide work

9 years ago

The Brent Saunders way: Allergan pays $95M for its next stepping stone to a bigger pipeline

9 years ago

Another old drug looks for a second coming at the FDA, this time for Duchenne MD

9 years ago

Microbiome upstart Vedanta teams up with NYU Langone scientist on checkpoint drugs

9 years ago

An introduction to the Endpoints 100

9 years ago

AstraZeneca doubles down on Moderna, invests $140M in $1.5B-plus biotech

9 years ago

Heron shares fly up after FDA (finally) approves its drug to rein in chemo side effects

9 years ago

Frustrated Eli Lilly may have to settle for a lonely last-place finish in the blockbuster CDK 4/6 race

9 years ago

Spark adds fresh evidence that pioneering gene therapy could be a game changer for patients

9 years ago

Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal

9 years ago

Protocols: Valeant sheds assets, but falls short on consensus; What if voters got a chance to weigh in on your trial?

9 years ago

As gene therapy rivals advance, Biogen moves closer to spinning out hemophilia drugs, R&D

9 years ago

FDA clears a Phase III path for Biogen’s BACE drug for Alzheimer’s

9 years ago

Will AbbVie bite? Decision time after Ablynx's rheumatoid arthritis drug fails a key study

9 years ago

Now a two-time loser, AstraZeneca’s hopes for selumetinib dwindle after another PhIII flop

9 years ago

Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016

9 years ago

Protocols: Allergan disses giant leaps, concentrates on stepping stones; AstraZeneca also gets a boost from ...

9 years ago

Acetylon can say goodbye to buyout and a $1B-plus in Celgene biobucks

9 years ago

Novartis's asthma ‘wonder drug’ basks in the bright spotlight of a UK media frenzy

9 years ago

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study

9 years ago

Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies

9 years ago

First page Previous page 1169 1170 117111721173 1174 1175 Next page Last page